After being fired, I became the light of medicine

Chapter 84 Emergency Meeting on Medical Insurance

the other side,
In Jiangsu Province, the atmosphere in the general manager's office of Hengrui Medicine is far from relaxed.

"Wenping, do you think the 90% chance of cure they advertise will be successful?"

Su Wenping was sitting on a chair and did not answer Su Lin's question immediately after hearing it.

After being silent for about two or three seconds, he slowly said:

"Boss, based on my understanding of Qingshan Pharmaceutical, it should be almost correct."

"Yeah, that's right..."

Su Lin sighed slightly and said:

"At the beginning, we were full of hope to compete with Gilead for the 'Starlight Project', but no one could have imagined that we would fail, and Gilead would not succeed either. Instead, Qingshan Pharmaceuticals broke through the siege so quickly!"

“They’re moving too fast.”

Su Lin also sighed helplessly, and his mood was obviously much lower.

Actually,
He really paid enough attention to Tsingshan Pharmaceutical, especially when "QS-001" just entered the Phase II clinical trial, he immediately paid close attention and began to collect information.

But even so, Qingshan Pharmaceutical's progress far exceeded his expectations.

At this time, Su Lin continued:

"Never mind, Wenping, since they have made a breakthrough, let's stop here with our hepatitis B drug 'HR-006'."

"You will inform the R&D department later that the 'HR-006' project is officially stopped and all R&D personnel will be transferred to other projects."

Hearing this, Su Wenping was stunned at first, and then a trace of regret flashed through his mind.

During this year, he kept an eye on the "HR-006" project almost every day. It would be a lie to say that he had no feelings for it at all!
and……

The "HR-006" project is not completely without progress. On the contrary, it is progressing smoothly, but not as fast as Tsingshan Pharmaceutical's "QS-001".

If we keep persisting, "HR-006" may be able to cure hepatitis B in its own way.

Thinking of this, he couldn't help but say:

"Boss, the HR-006 project is actually progressing quite well. In the past few months, the effective rate of preventing the synthesis of hepatitis B has reached 40%, and the latest test last month has increased it to 50%."

"If we persist a little longer, we may be able to cure hepatitis B in another way. Moreover, our method has almost no toxic side effects and is much better than Qingshan Pharmaceutical's..."

Before he finished speaking, Su Lin waved his hand and interrupted:
"That's not necessary, Wenping. There are about 100 million hepatitis B patients in China."

"Once Qingshan Pharmaceutical's drugs are launched on the market, they will quickly take over the market. By then, even if we make a breakthrough, we will only be eating leftovers and won't make much money."

"If you have this time, you might as well focus on developing other drugs that are more likely to make money."

Su Wenping was silent. Su Lin's consideration was to maximize the company's commercial profits, which was not wrong.

"In that case, do you want to organize all the researchers in the project team to learn about Qingshan Pharmaceutical's unique approach to 'Ekofovir'?"

"Their approach to solving the hepatitis B virus problem is very novel and may help us develop other drugs."

Su Lin was silent for a moment, and finally shook his head:

"There is no rush for now. Our multiple drug development teams are at a critical juncture."

"As you know, we face many competitors for several targeted drugs under development. If we let them get ahead, we will lose a lot of profits."

"So, let's talk about it after we have achieved results and are done with this busy period." Su Lin pursed his lips and said nothing more. For the first time, he felt that he and President Su had some differences on the research and development issue.

Suddenly, he thought of Qingshan Pharmaceutical and Zhang Yang.

If Zhang Yang encountered such a thing, what would he do?

If "HR-006" is successfully announced before "QS-001", will Zhang Yang simply give up "QS-001"?

he does not know.

……

Su Lin’s choice is neither right nor wrong.

Not only him, after Qingshan Pharmaceutical's "Ekofovir" Phase II clinical data was released and successfully approved for Phase III clinical trials, most domestic pharmaceutical companies stopped the research and development of their own hepatitis B projects.

Only a very small number of pharmaceutical companies have begun to try to learn the toxicity of "Afovir", hoping to apply this idea to other cCDNA covalently closed viruses like hepatitis B.

For example: HIV, Ebola and coronavirus.

Zhang Yang was not aware of the choices made by the pharmaceutical companies. With 600 participants signing up for the Phase III clinical trial, the Phase III clinical trial of "Ekofovir" officially began on November 11.

This time, since each group had nearly 100 participants, right after the drugs were distributed,

Many patients started "drug trial live broadcasts" on multiple platforms such as the Hepatitis B Forum, Douyin, and Bilibili, and began to record the changes in their daily medication process.

Originally, participants in clinical trials were required to sign a confidentiality agreement, and subjects were not allowed to send data to the Internet.

But "Ekofovir" itself is a completely branded product, and there is no possibility of leaking any commercial secrets. It can even be used for advertising, so Zhang Yang simply didn't care.

Gradually, large amounts of real data from human subjects have appeared on the Internet.

It was fine in the first two or three weeks, and the test results of the subjects had not turned negative; it was not until the fifth and sixth weeks that a large number of subjects turned negative and were cured.

Everyone began to truly realize that what Tsingshan Pharmaceutical said about the 90% cure rate in Phase III clinical trials was not just talk.

It might be true!

On January 1, the first batch of Phase III clinical trials of "Ekofovir" had just ended two days ago.
The organizers of the "Starlight Project": the "State Food and Drug Administration" and the "Innovative Drug Research and Development Center" urgently convened a seminar with 20 people in conjunction with the "National Health Commission", "Medical Insurance Bureau" and other departments.

The meeting was chaired by Zhou Hai, deputy director of the "Innovative Drug R&D Center" project department.

"Good afternoon, respected leaders, medical experts who have come from afar, and colleagues from all departments. Thank you for taking the time out of your busy schedule to attend this seminar."

"I'm sure everyone already knows the topic of the discussion. It's about a drug recently developed by Qingshan Pharmaceutical that can cure hepatitis B - 'Acofenprofovir'."

With the simple opening remarks, the conference room at the Shenzhen Innovative Drug Support Center gradually became quiet.

"Now the seminar will officially begin. First, let me give you a brief introduction to the current situation of 'Ikefenprofovir'."

"Please look at the screen."

Zhou Hai lightly pressed the projection pen in his hand, and a detailed data table appeared on the screen in front of the conference room.

"This is the clinical data of the second phase of the clinical trial of 'Ekofovir'. You can see that their cure rate has increased from 25% to 40%, and finally the last group reached 60%!"

"And yesterday, we got all the data from their latest first batch of Phase III clinical trials."

(End of this chapter)